Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
NPJ Breast Cancer|September 29, 2023
Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes-exploratory analysis of the Clalit registryShlomit S Shachar, Michelle Leviov, Rinat Yerushalmi, et al.
NPJ Breast Cancer|June 2, 2023
Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort studyOfer Rotem, Idit Peretz, Michelle Leviov, et al.
The New England Journal of Medicine|August 16, 2018
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA MutationJennifer K Litton, Hope S Rugo, Johannes Ettl, et al.
JNCI Cancer Spectrum|April 28, 2020
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care ChemotherapyHope S Rugo, Johannes Ettl, Sara A Hurvitz, et al.
Breast Cancer Research and Treatment|August 2, 2019
The yield of full BRCA1/2 genotyping in Israeli Arab high-risk breast/ovarian cancer patientsRinat Bernstein-Molho, Inbal Barnes-Kedar, Mark D Ludman, et al.
Lancet (London, England)|April 22, 2023
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trialFabrice André, Yeon Hee Park, Sung-Bae Kim, et al.
JAMA Oncology|January 22, 2021
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical TrialHope S Rugo, Seock-Ah Im, Fatima Cardoso, et al.
European Journal of Cancer (Oxford, England : 1990)|April 29, 2025
Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort studyIsotta Martha Magaton, Eva Blondeaux, Anne-Sophie Hamy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2022
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 TrialHope S Rugo, Seock-Ah Im, Fatima Cardoso, et al.
The New England Journal of Medicine|June 6, 2022
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerShanu Modi, William Jacot, Toshinari Yamashita, et al.
Pageof 10